Zacks Research Has Bullish Forecast for EW Q3 Earnings

Edwards Lifesciences Co. (NYSE:EW) – Equities research analysts at Zacks Research lifted their Q3 2025 earnings estimates for shares of Edwards Lifesciences in a research report issued to clients and investors on Wednesday, November 20th. Zacks Research analyst R. Department now forecasts that the medical research company will earn $0.60 per share for the quarter, up from their previous forecast of $0.59. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.57 per share.

Other equities analysts also recently issued research reports about the company. Royal Bank of Canada reduced their price objective on Edwards Lifesciences from $85.00 to $75.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Piper Sandler dropped their price objective on shares of Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating for the company in a report on Friday, October 25th. Barclays reduced their target price on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a research note on Monday, September 9th. Robert W. Baird cut their price target on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a report on Friday, October 25th. Finally, Jefferies Financial Group cut Edwards Lifesciences from a “buy” rating to a “hold” rating and decreased their price objective for the company from $85.00 to $70.00 in a report on Wednesday, September 18th. Seventeen analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, Edwards Lifesciences presently has an average rating of “Hold” and a consensus target price of $75.67.

Edwards Lifesciences Stock Performance

EW opened at $71.26 on Monday. The firm has a market capitalization of $42.03 billion, a PE ratio of 10.28, a PEG ratio of 3.96 and a beta of 1.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences has a twelve month low of $58.93 and a twelve month high of $96.12. The firm’s 50-day moving average price is $67.74 and its 200 day moving average price is $75.48.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting the consensus estimate of $0.67. The company had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. Edwards Lifesciences’s quarterly revenue was up 8.9% on a year-over-year basis. During the same period in the previous year, the business earned $0.59 EPS.

Insider Buying and Selling

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total transaction of $327,850.00. Following the sale, the vice president now directly owns 46,936 shares in the company, valued at $3,077,593.52. This trade represents a 9.63 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Larry L. Wood sold 25,000 shares of the business’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the sale, the insider now directly owns 198,526 shares of the company’s stock, valued at $13,084,848.66. The trade was a 11.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 40,000 shares of company stock worth $2,657,000. Company insiders own 1.27% of the company’s stock.

Hedge Funds Weigh In On Edwards Lifesciences

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. First Community Trust NA acquired a new stake in Edwards Lifesciences during the 2nd quarter worth approximately $29,000. FSA Wealth Management LLC acquired a new stake in shares of Edwards Lifesciences during the third quarter worth $30,000. Prospera Private Wealth LLC acquired a new stake in shares of Edwards Lifesciences during the third quarter worth $32,000. Avior Wealth Management LLC grew its position in Edwards Lifesciences by 138.7% in the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after buying an additional 308 shares during the last quarter. Finally, Webster Bank N. A. acquired a new position in shares of Edwards Lifesciences during the second quarter worth about $39,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.